|By Marketwired .||
|May 15, 2014 07:00 AM EDT||
MOUNTAIN VIEW, CA--(Marketwired - May 15, 2014) - VIVUS (NASDAQ: VVUS) today announced that a poster describing results of an analysis of the association between weight loss with Qsymia
About the Presentation
Session: Diabetes/Prediabetes, Hypoglycemia, Lipid/Cardiovascular Disorders, Obesity, Reproductive Endocrinology, and Other
Abstract Title: Effect of Weight Loss on Concomitant Medication Costs in Obese/Overweight Individuals With Edmonton Obesity Staging System Stage 3 Obesity Receiving Phentermine/Topiramate Extended-Release
Authors: Timothy Church, Arya M. Sharma, Sarah A. Odeh
Date/Time: Thursday, May 15, 2014 - 9:45-11:00am PDT
Qsymia is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.
The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.
Important Safety Information
Qsymia can cause fetal harm. Females of reproductive potential should have a negative pregnancy test before treatment and monthly thereafter and use effective contraception consistently during Qsymia therapy. If a patient becomes pregnant while taking Qsymia, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.
The most commonly observed side effects in controlled clinical studies, 5% or greater and at least 1.5 times placebo, include paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth.
VIVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health. For more information about the company, please visit www.vivus.com.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS's Form 10-K for the year ended December 31, 2013, as amended by the Form 10-K/A filed on April 30, 2014, and periodic reports filed with the Securities and Exchange Commission.
May. 5, 2016 03:00 AM EDT Reads: 1,321
May. 5, 2016 02:00 AM EDT Reads: 1,287
May. 5, 2016 01:45 AM EDT Reads: 1,228
May. 5, 2016 01:00 AM EDT Reads: 1,314
May. 5, 2016 12:45 AM EDT Reads: 1,381
May. 5, 2016 12:00 AM EDT Reads: 1,199
May. 4, 2016 11:45 PM EDT Reads: 1,262
May. 4, 2016 09:00 PM EDT Reads: 1,427
May. 4, 2016 07:30 PM EDT Reads: 1,707
May. 4, 2016 05:30 PM EDT Reads: 1,409
May. 4, 2016 05:15 PM EDT Reads: 463
May. 4, 2016 05:00 PM EDT Reads: 1,334
May. 4, 2016 04:30 PM EDT Reads: 832
May. 4, 2016 03:30 PM EDT Reads: 694